Background: Social media use has grown across healthcare delivery and practice, with dramatic changes occurring in response to the coronavirus (COVID-19) pandemic. The purpose of this study was to conduct a comprehensive systematic review to determine the current landscape of social media use by (1) orthopaedic surgery residencies/fellowship training programs and (2) individual orthopaedic surgeons and the change in use over time. Methods: We searched 3 electronic databases (PubMed, MEDLINE, and Embase) from their inception to April 2022 for all studies that analyzed the use of social media in orthopaedic surgery. Two reviewers independently determined study eligibility, rated study quality, and extracted data. Methodology was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: Twenty-eight studies were included, of which 11 analyzed social media use by orthopaedic surgery residency and fellowship training programs and 17 examined its use by individual orthopaedic surgeons. Among residency and fellowship programs, Instagram was identified as the most common platform used, with 42% to 88% of programs reporting program-specific Instagram accounts, followed by Twitter/X (20%-52%) and Facebook (10%-38%). Social media was most commonly used by programs for recruitment and information dissemination to prospective residency applicants (82% and 73% of included studies, respectively). After the start of the COVID-19 pandemic, there was a 620% and 177% increase in the number of training programs with Instagram and Twitter/X accounts, respectively. Individual use of social media ranged from 1.7% to 76% (Twitter/X), 10% to 73% (Facebook), 0% to 61% (Instagram), 22% to 61% (LinkedIn), and 6.5% to 56% (YouTube). Conclusions: Instagram, Twitter/X, and Facebook are the premier platforms that patients, residency applicants, and institutions frequent. With the continued growth of social media use anticipated, it will be critical for institutions and individuals to create and abide by guidelines outlining respectful and professional integration of social media into practice. Level of Evidence: Level IV.
Coronary Artery Calcification: Current Concepts and Clinical Implications
Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Its role in atherosclerosis holds great interest because the presence and burden of coronary calcification provide direct evidence of the presence and extent of coronary artery disease; furthermore, CAC predicts future events independently of concomitant conventional cardiovascular risk factors and to a greater extent than any other noninvasive biomarker of this disease. Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood. This review summarizes the current understanding and literature on CAC. It outlines the pathophysiology of CAC and reviews laboratory, histopathological, and genetic studies, as well as imaging findings, to characterize different types of calcification and to elucidate their implications. Some patterns of calcification such as microcalcification portend increased risk of rupture and cardiovascular events and may improve prognosis assessment noninvasively. However, contemporary computed tomography cannot assess early microcalcification. Limited spatial resolution and blooming artifacts may hinder estimation of degree of coronary artery stenosis. Technical advances such as photon counting detectors and combination with nuclear approaches (eg, NaF imaging) promise to improve the performance of cardiac computed tomography. These innovations may speed achieving the ultimate goal of providing noninvasively specific and clinically actionable information.
Collegiate women’s wrestling body fat percentage and minimum wrestling weight values: time for revisiting minimal body fat percent?
Background: Nanoparticles (NPs) have been extensively utilized as a drug delivery system to control the release of therapeutic agents to treat cardiac injuries. However, despite the advantages of utilizing NP-based drug delivery for treating heart diseases, the current delivery system lacks specificity in targeting the cardiac tissue, thus limiting its application. Methods: We created three linear peptides, each consisting of 16–24 amino acids. These peptides were conjugated on the surface of NPs, resulting in the formation of cardiac targeting peptide (CTP)-NPs (designated as CTP-NP1, CTP-NP2, and CTP-NP3). To assess their effectiveness, we compared the binding efficiency of these three CTP-NPs to human and mouse cardiomyocytes. Additionally, we determined their distribution 24 h after injecting the CTP-NPs intravenously into adult C57BL/6J mice. Results: When compared to control NPs without CTP (Con-NPs), all three CTP-NPs exhibited significantly increased binding affinity to both human and mouse cardiomyocytes in vitro and enhanced retention in mouse hearts in vivo. A thorough assessment of the heart sections demonstrated that the binding specificity of CTP-NP3 to cardiomyocytes in vivo was significantly greater than that of Con-NPs. None of the three CTP-NPs were proven to cause cardiomyocyte apoptosis. Conclusions: Biocompatible and safe CTP-NP3 can target the heart via binding to cardiomyocytes. This approach of targeting specific molecules-coated NPs may help in delivering therapeutic compounds to cardiomyocytes for the treatment of heart diseases with high efficacy and low toxicity to other tissues.
Trends in comorbid chronic kidney disease and atrial fibrillation‐related cardiovascular mortality in the United States
AbstractBackgroundThe impact of chronic kidney disease (CKD) on atrial fibrillation outcomes (AF) is not well understood.MethodsWe conducted analyses of comorbid AF and CKD related death in the United States from 1999 to 2020 using descriptive epidemiology.ResultsAge‐adjusted mortality rates (AAMR) per 100,000 increased from 0.39 in 1999 to 1.65 in 2020. Non‐Hispanic populations (1.01) and nonmetropolitan areas (1.08) had higher AAMRs compared to Hispanic (0.62) and metropolitan (0.97) areas. Midwestern (1.11) and Western (1.13) US regions recorded the highest AAMRs.ConclusionsThese findings highlight the need for interventions to address AF death disparities in patients with CKD.
Abstract C095: KRAS mutation subtypes are associated with clinical and phenotypic differences in pancreatic ductal adenocarcinoma
Abstract Background: KRAS is a significant driver gene for pancreatic ductal adenocarcinoma (PDAC) and is present in up to 90% of PDAC cases. KRAS mutant (mt) PDAC tends to have worse prognosis compared to KRAS wild-type (wt) PDAC. However, the clinical and biological impact of the KRAS mutation subtypes (e.g. G12D, G12R, G12V, G12C and Q61) remains unclear. We sought to explore the clinical and molecular characteristics of the KRAS mt subtypes. Methods: We performed a retrospective review of patients with KRAS mt PDAC who underwent next generation sequencing at our institution from December 1, 2018 to December 1, 2021. We collected patient demographics, disease characteristics, clinical outcomes, DNA and RNA sequencing results via chart review. Bulk RNA-seq was performed via Tempus and The Cancer Genome Atlas. Count data were processed and separated by KRAS mutation subtype using a custom python script. Differential gene expression was performed using the DifSeq2 R package. Results: A total of 158 KRAS mt patients (at diagnosis, average age 63.8 years, 57% male, 88 (56%) Stage IV) were included. 10% of patients had KRAS Q61 mutation, 14% G12R, 30% G12V and 46% G12D; only 1.1% had the potentially actionable G12C mutation. G12R had a longer overall survival (OS) compared to the others (median 24.8 vs 17.5 months (m), p=0.05). Among patients with de novo metastatic disease, G12V had the lowest OS (median 9.8 vs 12.4 m, p=0.02). Between the KRAS mt subtypes, there were no statistically significant differences in tumor mutation burden, location of PDAC or subsequent metastasis, lines of treatment (average 2.3), age at diagnosis, gender, or stage at diagnosis. One hundred thirty-seven (87%) patients had at least one pathogenic somatic variant, 14 of which had statistically significant differences between KRAS mt subtypes. 82 (52%) patients had at least one RNA expression variant and bulk RNA-seq showed that each KRAS G12 mutation subtype had unique gene expression patterns, including several oncogenes and tumor suppressor genes. Conclusions: Our data suggest that KRAS mt subtypes may confer different clinically significant phenotypes of PDAC. We found G12R to be associated with improved prognosis compared to other KRAS mt subtypes and that among patients with de novo metastatic disease, G12V had the worst prognostic implication. As there were no statistically significant differences in patient demographics between the KRAS mt subtypes, we hypothesize survival differences are driven by biological phenotype. This is supported by our RNA-seq findings, which demonstrated unique gene expression patterns for each KRAS mt subtype. Citation Format: Alexander Xiao, Jack Korleski, Ryan Carr. KRAS mutation subtypes are associated with clinical and phenotypic differences in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr C095.
Ulnar Nerve Decompression With Subcutaneous Transposition
Background: Medial-sided elbow injuries are becoming increasingly common among throwing athletes due to overuse and increased specialization at early ages. High valgus stress and repetitive elbow flexion/extension during throwing not only affects the ligaments and dynamic support of the elbow, but commonly affects the ulnar nerve. Indications: Management of cubital tunnel syndrome is initially rest, therapy, and functional training; however, if conservative measures do not appropriately address the ulnar neuropathy, surgical decompression with subcutaneous transposition is a reliable treatment option. Technique Description: An incision is created over the medial epicondyle. The medial antebrachial cutaneous nerve is identified and protected. The ulnar nerve is identified and tagged with a vessel loop to allow for appropriate handling of the nerve. Decompression of the ulnar nerve begins proximally by spreading the tissues superficial to the ulnar nerve and splitting the fascia overlying it. Then, dissection deep to the nerve is performed. A small strip of the medial intermuscular septum will be used as a sling to hold the nerve securely in the transposed position. This is released proximally and the distal attachment to the medial epicondyle is left in place. Decompression is then continued distally by releasing the superficial fascia over the flexor carpi ulnaris (FCU) and a portion of the deep FCU muscle belly and fascia. The nerve is decompressed circumferentially, while preserving penetrating branches to the FCU as able. Ultimately, the ulnar nerve is decompressed 10 cm proximal and 10 cm distal to the medial epicondyle. The intermuscular septum is then pulled over the nerve, checked for appropriate length, and sutured in place both posterior and anterior to the ulnar nerve. Results: Symptom improvement after decompression and transposition is high (>90%); however, performance outcomes in overhead and throwing athletes is variable, and return to previous or higher level of play ranges from 60% to 90%. Discussion/Conclusion: Ulnar nerve decompression and transposition can reliably address underlying symptoms, but results are mixed for return to sport outcomes in overhead and throwing athletes. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.